Explain Atazanavir
Atazanavir (ATV, Reyataz) - Atazanavir (Medical Letter 2003; 45:89) is the first single-agent protease inhibitor with once-daily dosing. In clinical trials it has been similar to efavirenz or nelfinavir in lowering viral load in treatment-naïve patients. Atazanavir alone was less effective than lopinavir/ritonovir, but atazanavir/ritonavir was comparable to lopinavir/ritonavir in treatment-experienced patients .